Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study
Myélome multiple; Immunomodulation; Greffe autologue de cellules souches hématopoïétiques
Disciplines :
Hematology
Author, co-author :
Tangen, Jon-Magnus
Tierens, Anne
CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
BINSFELD, Marilène ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie biologique et immuno-hématologie
Olstad, Ole Kristoffer
Troseid, Anne-Marie Siebke
Wang, Junbai
Tjonnfjord, Geir Erland
Hetland, Geir
Language :
English
Title :
Immunomodulatory Effects of the Agaricus blazei Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study
R. Bataille and J.-L. Harrousseau, "Multiple myeloma", The New England Journal of Medicine, vol. 336, pp. 1657-1664, 1997.
A. Palumbo and K. Anderson, "Multiple myeloma", The New England Journal of Medicine, vol. 364, no. 11, pp. 1046-1060, 2011.
S. Y. Kristinsson, W. F. Anderson, and O. Landgren, "Improved long-term survival in multiple myeloma up to the age of 80 years", Leukemia, vol. 28, no. 6, pp. 1346-1348, 2014.
F. Firenzuoli, L. Gori, and G. Lombardo, "The medicinal mushroom Agaricus blazei murrill: review of literature and pharmaco-toxicological problems", Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 1, pp. 3-15, 2008.
Y. Fujimiya, Y. Suzuki, K.-I. Oshiman et al., "Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis", Cancer Immunology Immunotherapy, vol. 46, no. 3, pp. 147-159, 1998.
H. Kobayashi, R. Yoshida, Y. Kanada et al., "Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model", Journal of Cancer Research and Clinical Oncology, vol. 131, no. 8, pp. 527-538, 2005.
K. Sorimachi, K. Akimoto, and T. Koge, "Inhibitory effect of Agaricu blazei murill components on abnormal collagen fiber formation in human hepatocarcinoma cells", Bioscience, Biotechnology and Biochemistry, vol. 72, no. 2, pp. 621-623, 2008.
M. Endo, H. Beppu, H. Akiyama et al., "Agaritine purified from Agaricus blazei Murrill exerts anti-tumor activity against leukemic cells", Biochimica et Biophysica Acta-General Subjects, vol. 1800, no. 7, pp. 669-673, 2010.
H. Itoh, H. Ito, H. Amano, and H. Noda, "Inhibitory action of a (1-6)-β-D-glucan-protein complex (F III-2-b) isolated from Agaricus blazei Murill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism", The Japanese Journal of Pharmacology, vol. 66, no. 2, pp. 265-271, 1994.
K. Murakawa, K. Fukunaga, M. Tanouchi, M. Hosokawa, Z. Hossain, and K. Takahashi, "Therapy of myeloma in vivo using marine phospholipid in combination with Agaricus blazei Murill as an immune respond activator", Journal of Oleo Science, vol. 56, no. 4, pp. 179-188, 2007.
Y. Kimura, T. Kido, T. Takaku, M. Sumiyoshi, and K. Baba, "Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions", Cancer Science, vol. 95, no. 9, pp. 758-764, 2004.
S. Ohno, Y. Sumiyoshi, K. Hashine, A. Shirato, S. Kyo, and M. Inoue, "Phase I clinical study of the dietary supplement, Agaricus blazei Murill, in cancer patients in remission", Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 192381, 9 pages, 2011.
W.-S. Ahn, D.-J. Kim, G.-T. Chae et al., "Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy", International Journal of Gynecological Cancer, vol. 14, no. 4, pp. 589-594, 2004.
S. Bernardshaw, G. Hetland, L. K. Ellertsen, A. M. A. Tryggestad, and E. Johnson, "An extract of the medicinal mushroom Agaricus blazei Murill differentially stimulates production of pro-inflammatory cytokines in human monocytes and human vein endothelial cells in vitro", Inflammation, vol. 29, no. 4-6, pp. 147-153, 2005.
D. T. Førland, E. Johnson, A. M. A. Tryggestad, T. Lyberg, and G. Hetland, "An extract based on the medicinal mushroom Agaricus blazei Murill stimulates monocyte-derived dendritic cells to cytokine and chemokine production in vitro" Cytokine, vol. 49, no. 3, pp. 245-250, 2010.
G. Hetland, A. M. A. Tryggestad, T. Espevik et al., "The medicinal and antitumor mushroom agaricus blazeii murill activates NF-kappaB via TLR2 in monocytic cells and induces expression of cell surface markers and production of cytokines in human monocyte-derived dendritic cells (MDDC) in vitro", European Journal of Cancer Supplements, vol. 8, no. 5, p. 65, 2010.
J. M. Tangen, A. M. A. Tryggestad, and G. Hetland, "Stimulation of human monocytic cells by the medicinal mushroom Agaricus blazei Murill induces expression of cell surface markers associated with activation and antigen presentation", Applied Scientific Reports, vol. 1, no. 1, p. 1, 2014.
L. K. Ellertsen, G. Hetland, E. Johnson, and B. Grinde, "Effect of a medicinal extract from Agaricus blazei Murill on gene expression in a human monocyte cell line as examined by microarrays and immuno assays", International Immunopharmacology, vol. 6, no. 2, pp. 133-143, 2006.
B. Grinde, G. Hetland, and E. Johnson, "Effects on gene expression and viral load of a medicinal extract from Agaricus blazei in patients with chronic hepatitis C infection", International Immunopharmacology, vol. 6, no. 8, pp. 1311-1314, 2006.
E. Johnson, D. T. Førland, L. Saetre, S. V. Bernardshaw, T. Lyberg, and G. Hetland, "Effect of an extract based on the medicinal mushroom Agaricus blazeii Murill on release of cytokines, chemokines and leukocyte growth factors in human blood ex vivo and in vivo", Scandinavian Journal of Gastroenterology, vol. 47, no. 9, pp. 984-992, 2012.
D. T. Førland, E. Johnson, L. Saetre, T. Lyberg, I. Lygren, and G. Hetland, "Effect of an extract based on the medicinal mushroom Agaricus blazeii Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease", Scandinavian Journal of Immunology, vol. 73, no. 1, pp. 66-75, 2011.
S. Engdal and O. G. Nilsen, "In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients", Phytotherapy Research, vol. 23, no. 7, pp. 906-912, 2009.
S. Lenhoff, M. Hjorth, J. Westin et al., "Impact of age on survival after intensive therapy for multiple myeloma: a population based study by the Nordic Myeloma Study Group", British Journal of Haematology, vol. 133, no. 4, pp. 389-396, 2006.
P. O. Hofgaard, H. C. Jodal, K. Bommert et al., "Anovelmouse model for multiple myeloma (MOPC315. BM) that allows non invasive spatiotemporal detection of osteolytic disease", PLoS ONE, vol. 7, no. 12, Article ID e51892, 2012.
J. Wang, "Computational biology of genome expression and regultation-a review of microarray bioinformatics", Journal of Environmental Pathology, Toxicology and Oncology, vol. 27, no. 3, pp. 157-159, 2008.
J. Wang, T. H. B, I. Jonassen, O. Myklebost, and E. Hovig, "Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data", BMC Bioinformatics, vol. 4, Article60, 2003.
P. R. Greipp, J. San Miguel, B. G. Durie et al., "International staging system for multiple myeloma", Journal of Clinical Oncology, vol. 23, no. 15, pp. 312-320, 2005.
B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., "International uniform response criteria for multiple myeloma", Leukemia, vol. 20, no. 9, pp. 1467-1473, 2006.
N. Gulbrandsen, F. Wisløff, E. Nord, S. Lenhoff, M. Hjorth, and J. Westin, "Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma", European Journal of Haematology, vol. 66, no. 5, pp. 328-336, 2001.
C. A. Dinarello, "The interleukin-1 family: 10 years of discovery", The FASEB Journal, vol. 8, no. 15, pp. 1314-1325, 1994.
K. Chauffier, J. London, C. Beaudouin, and B. Fautrel, "Indications of anakinra", Presse Medicale, vol. 38, no. 5, pp. 799-807, 2009.
T. Lequerre, P. Quartier, D. Rosellini et al., "Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemiconset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France", Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 302-308, 2008.
C. A. Dinarello, "Why not treat human cancer with interleukin-1 blockade?" Cancer and Metastasis Reviews, vol. 29, no. 2, pp. 317-329, 2010.
R. K. Gherardi, L. Belec, M. Soubrier et al., "Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome", Blood, vol. 87, no. 4, pp. 1458-1465, 1996.
J. A. Lust and K. A. Donovan, "The role of interleukin-1 β in the pathogenesis of multiple myeloma", Hematology/Oncology Clinics of North America, vol. 13, no. 6, pp. 1117-1125, 1999.
J. A. Lust, M. Q. Lacy, S. R. Zeldenrust et al., "Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1/5-induced interleukin 6 production and the myeloma proliferative component", Mayo Clinic Proceedings, vol. 84, no. 2, pp. 114-122, 2009.
S. Dubucquoi, P. Desreumaux, A. Janin et al., "Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion", The Journal of Experimental Medicine, vol. 179, no. 2, pp. 703-708, 1994.
T. W. Wong, H. Kita, C. A. Hanson, D. K. Walters, B. K. Arendt, and D. F. Jelinek, "Induction of malignant plasma cell proliferation by eosinophild", PLoS ONE, vol. 8, no. 7, ArticlelD e70554, 2013.
T. J. Fry and C. L. Mackall, "Interleukin-7: from bench to clinic", Blood, vol. 99, no. 11, pp. 3892-3904, 2002.
M. Condomines, J.-L. Veyrune, M. Larroque et al., "Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy", The Journal of Immunology, vol. 184, no. 2, pp. 1079-1084, 2010.
D. Haribhai, J. B. Williams, S. Jia et al., "A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity", Immunity, vol. 35, no. 1, pp. 109-122, 2011.
G. J. Bates, S. B. Fox, C. Han et al., "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse", Journal of Clinical Oncology, vol. 24, no. 34, pp. 5373-5380, 2006.
M. Beyer, M. Kochanek, K. Darabi et al., "Reduced frequencies and suppressive function of CD4+CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine", Blood, vol. 106, no. 6, pp. 2018-2025, 2005.
D. A. A. Vignali, L. W. Collison, and C. J. Workman, "How regulatory T cells work", Nature Reviews Immunology, vol. 8, no. 7, pp. 523-532, 2008.
K. Giannopoulos, W. Kaminska, I. Hus, and A. Dmoszynska, "The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma", British Journal of Cancer, vol. 106, no. 3, pp. 546-552, 2012.
C. Bryant, H. Suen, R. Brown et al., "Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and afavourableTreg/Th17balance", Blood Cancer Journal, vol. 3, no. 9, Articlee148, 2013.
M. Pasiarski, E. Grywalska, A. Kosmaczewska, S. GZzdz, and J. Rolmski, "The frequency of myeloid and lymphoid dendritic cells in multiple myeloma patients is inversely correlated with disease progression", Postepy Higieny i Medycyny Doswiadczalnej, vol. 67, pp. 926-932, 2013.
L. Berven, P. Karppinen, G. Hetland, and A. B. C. Samuelsen, "The polar high molecular weight fraction of the Agaricus blazei Murill extract, AndoSan, reduces the activity of the tumor-associated protease, legumain, in RAW 264.7 cells", Journal of Medicinal Food, 2014.
